We immunostained for phosphorylated tau at threonine 181 (pTau181), an early tau post-translational modification and established Alzheimer’s disease biomarker that has been reported in other mouse models with fibrillar amyloid [41–43]. The gene discussed is MAPT; the disease is Alzheimer disease.